~~<i id='8C09E35AF0'><strike id='8C09E35AF0'><tt id='8C09E35AF0'><pre id='8C09E35AF0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：fashion 2025-09-29 21:23:36 - browse：19985

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Deliver public health messages at the right time

hotspot

entertainment

focus

hotspot

Wikipedia

AdobeYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneyinmedic

WSS

Deliver public health messages at the right time

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

AltruBio raises $225 million to develop ulcerative colitis drug

Chemotherapy before breast cancer surgery might fuel metastasis

As health system earnings go up, health insurance stocks go down

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

hotspot

explore

hotspot

Activists slam private health insurers over coverage restrictions

Flagship, Pfizer team up in deal worth up to $7 billion

Peter Hotez and the public health issue of online harassment

15 die by electrocution after transformer explodes in northern India

Trump demands the U.S. pay no more for drugs than other countries … again

Crowdfunding for medical bills sidesteps core problem, author says

United colonoscopy coverage change 'may cost lives,' doctors say

Johnson & Johnson sues to stop Medicare negotiation

Cancer drug shortages should be causing more outrage

The effects of a landmark ruling on DNA ownership are becoming clearer

entertainment

Primary care doctor shortage won't be solved by free med school tuition

Empower primary care with adequate payments and technology

Welsh Carson private equity firm escapes from FTC antitrust case

Manchin plays down potential 3rd

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Flagship, Pfizer team up in deal worth up to $7 billion

focus

focus

hotspot

Wikipedia